H.C. Wainwright initiated coverage of ANI Pharmaceuticals (ANIP) with a Buy rating and $84 price target The firm says the company has established itself as a “proven commercial execution success story” due to the delivery on its lead asset, Cortrophin Gel, as well as its generics business unit.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals presents preclinical data on Purified Cortrophin Gel use
- ANI Pharmaceuticals Highlights Financial Performance Amid Challenges
- ANI Pharmaceuticals Approves Key Proposals at Annual Meeting
- ANI Pharmaceuticals initiates Phase 4 trial of Purified Cortrophin Gel
- ANI Pharmaceuticals Releases May 2025 Financial Presentation